The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia’s clinical workflow and technology platforms.
InterVenn Biosciences and Aranscia have expanded their commercialization partnership to increase access to the GlycoKnow Ovarian cancer diagnostic test for clinicians and researchers.
The expansion builds on a multi-year agreement that provides InterVenn with access to Aranscia’s clinical workflow software solutions. The new scope broadens access to the diagnostic test across Aranscia’s network of health systems, oncology groups, and individual physicians. The companies also plan to use the technology platform to improve the efficiency of research studies and deliver longitudinal insights at the point of care.
“The Aranscia team is an ideal partner that understands and addresses tactical gaps in existing clinical workflows,” says Andrew Quong, CEO of InterVenn, in a release. “In addition, Aranscia’s technology platform helps to eliminate the friction in physician adoption, which is critical for executing clinical studies that support the value and utility of novel diagnostics in positively impacting a patient’s care journey.”
GlycoKnow Ovarian is a proprietary blood-based liquid biopsy test designed to help clinicians distinguish ovarian cancer from benign pelvic masses. By identifying the 80% of pelvic masses that are benign through a non-invasive test, the tool is intended to improve risk stratification and support surgical decision–making.
The test measures serum glycopeptides and uses an algorithm to assess the likelihood of malignancy. It is intended for use in women 18 years of age or older with a documented pelvic mass for which surgical intervention is being considered. According to InterVenn, the test is an adjunct to, and not a replacement for, standard clinical and radiological evaluation.
“The pace at which we have advanced our technical and commercial partnership with InterVenn from vision to production underscores Aranscia’s proven commitment to speed-to-value in precision medicine,” says Bryon Cipriani, CEO of Aranscia, in a release. “This is only the beginning of what we believe will be a strong long-term relationship that will help bring the benefit of glycoproteomics into practice for providers, researchers, and most importantly, the patients they serve.”
InterVenn performs the testing in its clinical laboratory, which is certified under the Clinical Laboratory Improvement Amendments of 1988 and complies with College of American Pathologists requirements. GlycoKnow Ovarian is available as a laboratory-developed test and has not been cleared or approved by the Food and Drug Administration.
ID 37079485 © Shawn Hempel | Dreamstime.com
